ArticleBMC ophthalmology2025
Racecadotril induced bilateral uveal effusion: a case report.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUveal effusion is a sight threatening condition, due to possible acute angle-closure glaucoma and maculopathy. We present a case of bilateral uveal effusion after taking racecadotril, an enkephalinase inhibitor used as a medical treatment for diarrhea. Uveal effusion after the use of racecadotril has not been described in literature. CASE PRESENTATION: A 76-year-old woman presented with blurred vision in both eyes. Fundoscopy and B-scan ultrasound showed bilateral choroidal effusion. The anterior chamber was narrow, but the intra ocular pressure remained normal. The medication review showed that the only recently added medication was racecadotril. Other potential causes of uveal effusion were excluded. Topical steroids and atropine were started. After cessation of racecadotril, a complete resolution of the uveal effusion was observed.
conclusionsThis case of bilateral uveal effusion was probably caused by racecadotril, since this was the only recently started drug, and we observed a complete resolution of the effusion after cessation of the drug. It is possible that the increase in enkephalins caused by racecadotril intake, leads to changes in the choroid, causing choroidal effusion. It is important to recognize uveal effusion as a rare side effect of racecadotril, because of its possible sight threatening character.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.